Advancing Technologies in Cell and Gene Therapy

Along the Road to 50 States, Gustavo Mahler, Managing Partner for Dynamk Capital, speaks with Nigel about the importance of technology in cell and gene therapy.

Gustavo Mahler, Ph.D.

Dr. Gustavo Mahler is a Venture Partner of Dynamk Capital LLC, having served as an Advisor to Dynamk since 2017. In 2015, Dr. Mahler became CEO of CMC Biologics, and he was a key player in the sale of CMC Biologics to the Asahi Glass Corporation in 2017. Dr. Mahler holds a Ph.D. in Biochemistry from the University of Buenos Aires, an MBA from the University of Madrid and a Leadership and Management Certification from MIT Sloan School of Management.